NALOXONE HCL

The U.S. FDA approved Naloxone HCl on 18 November 2015. It is indicated for reversal of opioid overdose and neonatal abstinence syndrome (NAS). It is used in combination with opioid maintenance therapy and for reversal in pain management settings.

Naloxone HCL is primarily used to swiftly reverse opioid overdoses, restoring normal respiration and consciousness by blocking opioid receptors in the brain. It is a crucial life-saving medication in emergencies involving opioids.

Naloxone HCL is administered intravenously (IV), intramuscularly (IM), intranasally (through the nose), or subcutaneously (under the skin). The choice of administration route may depend on the situation and the training level of the person providing the medication.

The primary side effect of Naloxone HCL is the induction of opioid withdrawal symptoms in those dependent on opioids, which include restlessness, agitation, nausea, vomiting, diarrhea, sweating, and muscle aches. Other possible, though less common, side effects may include nasal irritation and a transient increase in heart rate. Despite these side effects, the life-saving benefits of this medication in reversing opioid overdoses significantly outweigh the potential discomfort caused by withdrawal.

Naloxone HCL can precipitate opioid withdrawal symptoms in individuals who are physically dependent on opioids. This can be uncomfortable but is generally not life-threatening. These symptoms may include restlessness, agitation, nausea, vomiting, diarrhea, muscle aches, and increased heart rate. After it reverses the effects of opioids, there is a risk of the person experiencing a return of respiratory depression as the naloxone wears off. Using an insufficient dose of this medication may result in an incomplete reversal of opioid effects, leaving the person at risk of ongoing respiratory depression.

Precautions when using Naloxone HCL include being prepared to manage opioid withdrawal in opioid-dependent individuals, continuous monitoring for potential rebound respiratory depression, ensuring correct dosing to avoid incomplete reversal, using unexpired medication, vigilance for rare allergic reactions, seeking professional medical care for the underlying overdose, and following dosing guidelines while monitoring closely in pediatric, elderly, and liver-impaired populations.

Persons administering Naloxone HCL should be prepared to manage withdrawal symptoms if they occur. When using it as a nasal spray, ensure the nozzle is not obstructed and delivered correctly into the nostrils for optimal effectiveness. In cases of severe opioid overdose, multiple doses of naloxone may be necessary due to the duration of action of some opioids. This should be done under medical supervision, as its effects can wear off before the opioids have cleared the system. Do not use if it is past its expiration date, as expired medication may not be as effective in reversing an overdose. Check for any allergies to this medication before administration. Be aware that individual responses to this medication may vary; some patients may require higher or more frequent doses.

Mercury Pharma International Ltd, Electronic Medicines Compendium (EMC), [Revised on 19th Nov 2019] [Accessed on 27th Sept 2023], https://www.medicines.org.uk/emc/product/3590/pil#gref Christian Lüscher, Drugs of Abuse, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 575-589.